GW Pharmaceuticals unveiling U.S. company name at Epilepsy Meeting
GW Pharmaceuticals will unveil its new U.S. operating name, Greenwich Biosciences, when the company announces results from two completed Epidiolex Phase 3 trials, one in Lennox-Gastaut syndrome and one in Dravet syndrome, at the American Epilepsy Society Annual Meeting, December 2-6, 2016, in Houston, Texas. For the first time, company-sponsored activities will be conducted under Greenwich Biosciences, Inc., GW's new name for its operating unit in the United States. Greenwich Biosciences, headquartered in Carlsbad, California, is incorporated in the United States and 100% owned by UK-based GW Pharmaceuticals plc. As the corporate parent, GW will remain the publicly-traded entity, be responsible for regulatory filings in the United States, and control the ongoing development and intellectual property associated with Epidiolex and the rest of the company's cannabinoid pipeline.